DCGO · DocGo Inc.
The AI's read
DocGo reported Q2 revenue down to $73.4M from $80.4M as migrant projects wound down, but non-migrant revenue rose 19% and adjusted EBITDA loss improved from $10.3M to $6.3M. They also announced the acquisition of Hicuity Health, which brings $65M revenue and $4.5M adjusted EBITDA and management is shooting for a positive adjusted EBITDA run rate by end-2026. The market already punished the stock, down about 5% and RSI near 33, so some negative reaction is priced. The numbers show operational progress, but the Hicuity deal and synergy claims need proof before the market rewards the name. We lean mixed: the acquisition and margin improvement are constructive, but revenue decline and integration risk cap upside. In this choppy regime we'd want to see realized cost synergies and clear EBITDA momentum before getting more bullish on the story.